Cost-effectiveness of biologic compared with conventional synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis: a Register study

Joensuu Jaana T.; Aaltonen Kalle J.; Aronen Pasi; Sokka Tuulikki; Puolakka Kari; Tuompo Riitta; Korpela Markku; Vasala Mikko; Ilva Kirsti; Nordstrom Dan; Blom Marja

首页> 外文期刊>Rheumatology >Cost-effectiveness of biologic compared with conventional synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis: a Register study

【24h】

Cost-effectiveness of biologic compared with conventional synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis: a Register study

机译：登记研究研究了生物制剂与传统的合成疾病抗风湿药相比在类风湿关节炎中的成本效益

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Objective. The aim of this study was to explore the cost-effectiveness of biological DMARDs (bDMARDs) compared with conventional synthetic DMARDs (csDMARDs) for RA using real-world data from Finnish registers.

机译：目的。这项研究的目的是使用来自芬兰注册机构的真实数据，探索与传统合成DMARD（csDMARD）相比，RA的生物DMARD（bDMARD）的成本效益。

著录项

来源
《Rheumatology》 |2016年第10期|共9页
作者
Joensuu Jaana T.; Aaltonen Kalle J.; Aronen Pasi; Sokka Tuulikki; Puolakka Kari; Tuompo Riitta; Korpela Markku; Vasala Mikko; Ilva Kirsti; Nordstrom Dan; Blom Marja;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类免疫性疾病;
关键词
cost-effectiveness; rheumatoid arthritis; biological DMARDs; observational study;

机译：成本效益;类风湿关节炎;生物DMARDs;观察研究;

相似文献

外文文献
中文文献
专利

1. Cost-effectiveness of biologic compared with conventional synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis: a Register study [J] . Joensuu Jaana T., Aaltonen Kalle J., Aronen Pasi, Rheumatology . 2016,第10期

机译：登记研究研究了生物制剂与传统的合成疾病抗风湿药相比在类风湿关节炎中的成本效益
2. Cost-effectiveness of biologic compared with conventional synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis: a Register study [J] . Joensuu Jaana T., Aaltonen Kalle J., Aronen Pasi, Rheumatology . 2016,第10期

机译：与类风湿性关节炎患者的常规合成疾病改性抗风湿药物相比，生物学的成本效益：注册研究
3. Cost-effectiveness of biologics compared to conventional disease-modifying anti-rheumatic drugs (cDMARDs) for treatment of rheumatoid arthritis (RA): a register study [J] . Joensuu J. T., Aaltonen K. J., Aronen P., Scandinavian journal of rheumatology . 2015,第6期

机译：与传统的疾病缓解类抗风湿药（cDMARDs）相比，生物制剂治疗类风湿关节炎（RA）的成本效益：一项注册研究
4. No adverse physiological responses to infrared whole body hyperthermia in patients with rheumatoid arthritis and ankylosing spondylitis compared to healthy subjects. [C] . F.G.J. OOSTERVELD, E. KOOPMAN, J. OLDE SCHOLTENHUIS, Advances in biomedical research . 2010

机译：与健康受试者相比，类风湿性关节炎和强直性脊柱炎患者对红外全身热疗没有不利的生理反应。
5. “Don’t Rock the Boat”: A Qualitative Narrative Study Exploring Rheumatoid Arthritis Patients’ Experience of Illness and Biologics [D] . Rachich, Meagan . 2020

机译：“不要摇滚船”：探索类风湿性关节炎患者的疾病和生物学经验的定性叙事研究
6. Safety of abatacept compared with other biologic and conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: data from an observational study [O] . Gulsen Ozen, Sofia Pedro, Rebecca Schumacher, 2019

机译：类风湿关节炎患者中abatacept与其他生物制剂和传统的合成疾病缓解类风湿药的安全性：一项观察性研究的数据
7. Cost-effectiveness of biologic compared with conventional synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis: a Register study [O] . Jaana T. Joensuu, Kalle J. Aaltonen, Pasi Aronen, 2016

机译：与类风湿性关节炎患者的常规合成疾病改性抗风湿药物相比，生物学的成本效益：注册研究

Cost-effectiveness of biologic compared with conventional synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis: a Register study

摘要

著录项

相似文献

相关主题

期刊订阅